ArticleBrain and behavior2025
Exploring 1400 Plasma Metabolites and Polycystic Ovary Syndrome: A Bidirectional Mendelian Randomization Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Gut microbiota and metabolic dysregulation in polycystic ovary syndrome: effects of acupuncture as an adjunct toFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEvidence concerning the causal effects of blood metabolites on polycystic ovary syndrome (PCOS) risk remains scarce. A two-sample Mendelian randomization (MR) analysis was performed among individuals of European ancestry to establish a causal relationship between plasma metabolites and the risk of PCOS.
objectiveTo determine causal associations between 1400 blood metabolites and PCOS.
methodsUtilizing data from a GWAS, which encompasses over 1400 blood metabolites, bidirectional MR was employed to explore the potential causal associations between PCOS and these metabolites. Causal inference methods included inverse variance weighting, MR-Egger regression, weighted median, weighted mode, and simple mode approaches. Sensitivity analyses were performed to validate the robustness of the results. Reverse MR analyzed 1400 blood metabolites as outcomes and PCOS as the exposure.
resultsFifteen plasma metabolites, including methionine sulfoxide, N-acetylserine, and glycine, exhibited positive causal effects on PCOS risk. In contrast, 13 metabolites, including threonate, 7-methylguanine, and theophylline, demonstrated protective effects. Leave-one-out analysis confirmed the stability of the results, with no influential instrumental variables, and eliminated the impacts of heterogeneity and horizontal pleiotropy. Reverse MR revealed no evidence of causal associations between PCOS and the metabolites.
conclusionThirteen plasma metabolites were identified as protective factors for PCOS. Targeted modulation of these metabolites may improve metabolic dysfunction in patients, alleviating symptoms and enhancing quality of life. Further exploration of metabolite dynamics could advance mechanistic insights into PCOS pathogenesis and inform therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.